<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098328</url>
  </required_header>
  <id_info>
    <org_study_id>201901</org_study_id>
    <nct_id>NCT04098328</nct_id>
  </id_info>
  <brief_title>Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Mitral Regurgitation</brief_title>
  <acronym>EXPLORE MR</acronym>
  <official_title>Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Mitral Regurgitation (EXPLORE MR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polares Medical SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polares Medical SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early feasibility study, single-arm registry design
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First-In-Human
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement from baseline mitral regurgitation</measure>
    <time_frame>30 days</time_frame>
    <description>Grade 2+ or less as evaluated by 2D transthoracic echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success according to MVARC2 criteria</measure>
    <time_frame>24 hours</time_frame>
    <description>Absence of procedure mortality
Successful access, delivery and retrieval of investigation delivery system
Successful deployment and correct positioning of intended implant(s)
Freedom from emergency surgery/re-intervention related to device or access procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success according to MVARC2 criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of procedure mortality or stroke
Proper placement and positioning of device
Freedom from unplanned re-intervention related to device or access procedure
Continued intended safety and performance of the device:
No evidence of structural or functional failure
No device technical failure issues/complications
MR reduction to moderate or less without stenosis
Absence of major device or procedure-related SAE:
Death
Stroke
Life-threatening bleed
Major vascular complication
Major cardiac structural complication
No device technical failure issues/complications
Stage 2 or 3 AKI
MI or coronary ischemia requiring PCI or CABG
Shock, heart or respiratory failure requiring IV vasopressors, mechanical intervention or prolonged intubation
Valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success according to MVARC2 criteria</measure>
    <time_frame>30 days, 6 and 12 months, and 2 - 5 years post treatment</time_frame>
    <description>Absence of procedure mortality or stroke
Proper placement and positioning of device
Freedom from unplanned re-intervention related to device or access procedure
Continued intended safety and performance of the device:
No evidence of structural or functional failure
No device technical failure issues/complications
MR reduction to moderate or less without stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient success according to MVARC2 criteria</measure>
    <time_frame>30 days, 6 and 12 months, and 2 - 5 years post treatment</time_frame>
    <description>Device success
Patient returned to pre-procedure setting
No rehospitalization or reintervention for mitral regurgitation or heart failure
Functional improvement from baseline by one or more NYHA class
6MWT improvement from baseline by 50 metres or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate (%) of major adverse events as defined by MVARC2 criteria</measure>
    <time_frame>Procedure, discharge/7 days, 30 days, 6 and 12 months, and 2 - 5 years post treatment</time_frame>
    <description>All-cause mortality, hospitalization due to cardiac conditions, stroke or TIA, myocardial infarction, access site and vascular complications, bleeding complications, acute kidney injury up to 7 days post-procedure, and arrhythmias and conduction system disturbances</description>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inoperable or high surgical risk patients with symptomatic degenerative or functional
        mitral regurgitation (Grade 3+ or higher) with mitral valve anatomy deemed unsuitable, or
        off-label, to be treated with an approved edge-to-edge repair system.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older.

          2. Greater than moderate degenerative or functional mitral regurgitation (Grade 3+ or
             higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to
             study procedure

          3. Patient must present with an STS Score less than 10%

          4. High surgical risk for conventional mitral repair or replacement due to morphological
             criteria (e.g. leaflet or annulus calcifications) as assessed by the local heart team
             comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist
             experienced in treating mitral valve disease and heart failure

          5. Mitral valve anatomy deemed unsuitable to be treated with an approved edge-to-edge
             repair system (e.g., retracted posterior leaflet, lack of leaflet tissue, calcified or
             cleft posterior leaflet) as assessed by the local heart team comprised of a cardiac
             surgeon experienced in mitral valve surgery and a cardiologist experienced in treating
             mitral valve disease and heart failure

          6. Patient is approved by an independent Patient Eligibility Committee

          7. New York Heart Association (NYHA) Functional Class III or IV

          8. Patient willing to participate in study and provide signed EC-approved informed
             consent.

          9. Treating physician and patient agree that patient is able to return for all required
             post- procedure follow-up visits

         10. Women of child-bearing potential have a negative pregnancy test

        Exclusion Criteria:

          1. Severe tricuspid regurgitation

          2. Severe aortic stenosis or insufficiency

          3. Severe mitral annulus calcification

          4. Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification

          5. Implanted vena cava filter

          6. Femoral veins with severe angulation and calcification

          7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan.

          8. Active infection or endocarditis

          9. Previous mitral valve surgery

         10. Prior orthotopic heart transplantation

         11. Pulmonary artery systolic hypertension &gt; 70mmHg

         12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus

         13. Left ventricular ejection fraction (LVEF) &lt; 30%

         14. Implant or revision of any pacing device &lt; 30 days prior to intervention

         15. Symptomatic coronary artery disease treated &lt; 30 days prior to study procedure

         16. Myocardial infarction requiring intervention &lt; 30 days prior to study procedure

         17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis),
             hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis

         18. Active peptic ulcer or upper gastrointestinal bleeding &lt; 90 days prior to study
             procedure

         19. Stroke &lt; 180 days prior to study procedure

         20. Severe renal insufficiency (creatinine &gt; 3.0 mg/dL) or patient requiring dialysis

         21. Cardiogenic shock at time of enrolment

         22. Hemodynamic instability requiring inotropic support or mechanical heart assistance

         23. Concurrent medical condition with a life expectancy of less than 2 years

         24. Pregnancy at time of enrolment

         25. History of bleeding diathesis or coagulopathy or leukopenia (WBC &lt; 3,000 mcL) or acute
             anemia (Hb &lt; 9 g/dL) or thrombocytopenia (platelets &lt; 50,000 cells mcL)

         26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or
             clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be
             pre-medicated

         27. Severe dementia or lack of capacity due to conditions that result in either inability
             to provide informed consent for the trial/procedure, prevent independent lifestyle
             outside of a chronic care facility, or will fundamentally complicate rehabilitation
             from the procedure or compliance with follow-up assessments

         28. Emergency situations

         29. Company employees or their immediate family members

         30. Patient is under guardianship

         31. Patient is participating in another clinical study for which follow-up is currently
             ongoing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura A Brenton</last_name>
    <role>Study Director</role>
    <affiliation>Polares Medical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Schaefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MarienKrankenhaus &amp; Asklepios Klinik St. Georg, Hamburg (DE)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Windecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital Bern, Bern (CH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura A Brenton</last_name>
    <phone>+1 313 919 8044</phone>
    <email>labrenton1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Praz, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

